Clinical Trials · NCT00683917
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Repros Therapeutics Inc.
- Enrollment
- 10
- Start date
- May 2008
- Locations
- 4 sites, United States, Mexico
- Primary endpoint
- The Primary Outcome Measure is the PK Characteristics of 25 mg and 50 mg Proellex.